Entera Price To Sales Ratio vs Capex To Revenue Analysis

ENTX Stock

USD 1.64 0.06 3.53%

Entera Bio financial indicator trend analysis is much more than just examining Entera Bio latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Entera Bio is a good investment. Please check the relationship between Entera Bio Price To Sales Ratio and its Capex To Revenue accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entera Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Entera Stock please use our How to Invest in Entera Bio guide.

Price To Sales Ratio vs Capex To Revenue

Price To Sales Ratio vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Entera Bio Price To Sales Ratio account and Capex To Revenue. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Entera Bio's Price To Sales Ratio and Capex To Revenue is 0.54. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Entera Bio, assuming nothing else is changed. The correlation between historical values of Entera Bio's Price To Sales Ratio and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Entera Bio are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Price To Sales Ratio i.e., Entera Bio's Price To Sales Ratio and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

0.54

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Entera Bio stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Entera Bio sales, a figure that is much harder to manipulate than other Entera Bio multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from Entera Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Entera Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entera Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Entera Stock please use our How to Invest in Entera Bio guide.At this time, Entera Bio's Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 51.15 in 2024, despite the fact that Tax Provision is likely to grow to (16.1 K).

	2023	2024 (projected)
Interest Income	854.5K	696.3K
Reconciled Depreciation	59K	84.1K

Interest Income Reconciled Depreciation

Entera Bio fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Property Plant Equipment
Total Assets		-0.75	0.75	0.2	0.82	0.82	0.81	0.61	-0.96	-0.72	-0.25	0.99	-0.24	-0.82	1.0	0.54	-0.67	0.32	0.76	-0.64	0.59	0.72	1.0	-0.6	-0.52	0.61
Short Long Term Debt Total	-0.75		-0.55	0.31	-0.86	-0.45	-0.86	-0.51	0.9	0.82	0.16	-0.73	0.25	0.65	-0.77	-0.56	0.75	-0.38	-0.83	0.8	-0.68	-0.91	-0.75	0.63	0.66	-0.63
Other Current Liab	0.75	-0.55		0.3	0.58	0.69	0.56	0.62	-0.73	-0.35	0.02	0.76	0.2	-0.55	0.75	0.17	-0.47	-0.07	0.47	-0.43	0.56	0.58	0.74	-0.42	-0.22	0.69
Total Current Liabilities	0.2	0.31	0.3		0.05	0.35	0.03	0.11	0.01	0.06	-0.34	0.19	0.24	-0.44	0.18	-0.09	-0.14	-0.11	0.0	0.03	0.14	-0.22	0.2	-0.25	0.08	0.23
Total Stockholder Equity	0.82	-0.86	0.58	0.05		0.54	1.0	0.6	-0.88	-0.88	-0.51	0.8	-0.31	-0.74	0.83	0.66	-0.96	0.43	0.93	-0.96	0.74	0.72	0.82	-0.92	-0.72	0.69
Other Liab	0.82	-0.45	0.69	0.35	0.54		0.52	0.41	-0.71	-0.32	-0.03	0.8	0.18	-0.58	0.81	0.25	-0.4	0.19	0.46	-0.34	0.5	0.51	0.81	-0.36	-0.12	0.63
Net Tangible Assets	0.81	-0.86	0.56	0.03	1.0	0.52		0.62	-0.88	-0.9	-0.53	0.79	-0.34	-0.74	0.82	0.68	-0.96	0.44	0.94	-0.97	0.75	0.72	0.82	-0.92	-0.75	0.67
Property Plant And Equipment Net	0.61	-0.51	0.62	0.11	0.6	0.41	0.62		-0.62	-0.56	-0.23	0.64	-0.09	-0.47	0.62	0.42	-0.54	0.03	0.58	-0.53	0.7	0.52	0.61	-0.5	-0.62	0.48
Net Debt	-0.96	0.9	-0.73	0.01	-0.88	-0.71	-0.88	-0.62		0.83	0.26	-0.96	0.29	0.78	-0.96	-0.64	0.73	-0.42	-0.86	0.74	-0.69	-0.85	-0.96	0.64	0.63	-0.66
Retained Earnings	-0.72	0.82	-0.35	0.06	-0.88	-0.32	-0.9	-0.56	0.83		0.64	-0.74	0.56	0.75	-0.74	-0.86	0.83	-0.66	-0.94	0.85	-0.72	-0.71	-0.73	0.77	0.9	-0.55
Accounts Payable	-0.25	0.16	0.02	-0.34	-0.51	-0.03	-0.53	-0.23	0.26	0.64		-0.31	0.52	0.4	-0.26	-0.74	0.63	-0.7	-0.62	0.58	-0.43	-0.02	-0.26	0.69	0.63	-0.31
Cash	0.99	-0.73	0.76	0.19	0.8	0.8	0.79	0.64	-0.96	-0.74	-0.31		-0.29	-0.78	0.99	0.63	-0.64	0.41	0.78	-0.61	0.62	0.71	0.99	-0.57	-0.56	0.62
Non Current Assets Total	-0.24	0.25	0.2	0.24	-0.31	0.18	-0.34	-0.09	0.29	0.56	0.52	-0.29		0.21	-0.27	-0.73	0.27	-0.58	-0.49	0.31	0.11	-0.2	-0.27	0.25	0.43	0.33
Long Term Debt	-0.82	0.65	-0.55	-0.44	-0.74	-0.58	-0.74	-0.47	0.78	0.75	0.4	-0.78	0.21		-0.81	-0.49	0.68	-0.32	-0.72	0.61	-0.62	-0.66	-0.82	0.65	0.58	-0.56
Cash And Short Term Investments	1.0	-0.77	0.75	0.18	0.83	0.81	0.82	0.62	-0.96	-0.74	-0.26	0.99	-0.27	-0.81		0.57	-0.67	0.35	0.78	-0.65	0.59	0.74	1.0	-0.6	-0.54	0.6
Common Stock Shares Outstanding	0.54	-0.56	0.17	-0.09	0.66	0.25	0.68	0.42	-0.64	-0.86	-0.74	0.63	-0.73	-0.49	0.57		-0.61	0.88	0.86	-0.63	0.54	0.54	0.56	-0.56	-0.69	0.33
Non Current Liabilities Total	-0.67	0.75	-0.47	-0.14	-0.96	-0.4	-0.96	-0.54	0.73	0.83	0.63	-0.64	0.27	0.68	-0.67	-0.61		-0.41	-0.89	0.99	-0.74	-0.58	-0.67	0.99	0.71	-0.67
Other Current Assets	0.32	-0.38	-0.07	-0.11	0.43	0.19	0.44	0.03	-0.42	-0.66	-0.7	0.41	-0.58	-0.32	0.35	0.88	-0.41		0.65	-0.43	0.41	0.34	0.34	-0.37	-0.51	0.31
Other Stockholder Equity	0.76	-0.83	0.47	0.0	0.93	0.46	0.94	0.58	-0.86	-0.94	-0.62	0.78	-0.49	-0.72	0.78	0.86	-0.89	0.65		-0.9	0.75	0.78	0.77	-0.84	-0.74	0.6
Total Liab	-0.64	0.8	-0.43	0.03	-0.96	-0.34	-0.97	-0.53	0.74	0.85	0.58	-0.61	0.31	0.61	-0.65	-0.63	0.99	-0.43	-0.9		-0.72	-0.63	-0.64	0.95	0.73	-0.64
Property Plant And Equipment Gross	0.59	-0.68	0.56	0.14	0.74	0.5	0.75	0.7	-0.69	-0.72	-0.43	0.62	0.11	-0.62	0.59	0.54	-0.74	0.41	0.75	-0.72		0.65	0.58	-0.69	-0.7	0.89
Short Long Term Debt	0.72	-0.91	0.58	-0.22	0.72	0.51	0.72	0.52	-0.85	-0.71	-0.02	0.71	-0.2	-0.66	0.74	0.54	-0.58	0.34	0.78	-0.63	0.65		0.72	-0.46	-0.45	0.53
Total Current Assets	1.0	-0.75	0.74	0.2	0.82	0.81	0.82	0.61	-0.96	-0.73	-0.26	0.99	-0.27	-0.82	1.0	0.56	-0.67	0.34	0.77	-0.64	0.58	0.72		-0.6	-0.53	0.59
Short Term Debt	-0.6	0.63	-0.42	-0.25	-0.92	-0.36	-0.92	-0.5	0.64	0.77	0.69	-0.57	0.25	0.65	-0.6	-0.56	0.99	-0.37	-0.84	0.95	-0.69	-0.46	-0.6		0.67	-0.63
Intangible Assets	-0.52	0.66	-0.22	0.08	-0.72	-0.12	-0.75	-0.62	0.63	0.9	0.63	-0.56	0.43	0.58	-0.54	-0.69	0.71	-0.51	-0.74	0.73	-0.7	-0.45	-0.53	0.67		-0.51
Property Plant Equipment	0.61	-0.63	0.69	0.23	0.69	0.63	0.67	0.48	-0.66	-0.55	-0.31	0.62	0.33	-0.56	0.6	0.33	-0.67	0.31	0.6	-0.64	0.89	0.53	0.59	-0.63	-0.51

Click cells to compare fundamentals

Entera Bio Account Relationship Matchups

Entera Bio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	16.7M	10.3M	26.0M	13.1M	11.8M	13.9M
Other Current Liab	3.8M	1.3M	2.5M	1.1M	740K	703K
Total Current Liabilities	4.6M	3.3M	3.2M	1.3M	1.1M	1.0M
Total Stockholder Equity	11.9M	6.7M	22.6M	11.8M	10.4M	10.9M
Net Tangible Assets	11.3M	6.1M	22.6M	11.8M	13.5M	14.2M
Property Plant And Equipment Net	462K	192K	395K	139K	488K	305.4K
Net Debt	(14.9M)	(8.2M)	(24.6M)	(12.2M)	(10.6M)	(11.2M)
Retained Earnings	(62.9M)	(72.9M)	(82.4M)	(95.5M)	(104.4M)	(99.2M)
Accounts Payable	334K	164K	166K	17K	83K	78.9K
Cash	15.2M	8.6M	24.9M	12.3M	11.0M	11.8M
Non Current Assets Total	1.1M	1.2M	658K	278K	508K	631.1K
Cash And Short Term Investments	15.2M	8.6M	24.9M	12.3M	11.0M	12.3M
Common Stock Shares Outstanding	12.1M	18.4M	26.1M	28.8M	29.0M	19.3M
Liabilities And Stockholders Equity	16.7M	10.3M	26.0M	13.1M	11.8M	13.9M
Non Current Liabilities Total	192K	324K	261K	32K	288K	273.6K
Other Current Assets	97K	261K	254K	294K	238K	209K
Other Stockholder Equity	63.4M	77.7M	105.0M	107.2M	114.7M	64.1M
Total Liab	4.8M	3.6M	3.4M	1.4M	1.4M	1.3M
Property Plant And Equipment Gross	462K	548K	395K	229K	488K	359.9K
Total Current Assets	15.6M	9.1M	25.3M	12.8M	11.3M	13.0M
Accumulated Other Comprehensive Income	13.1M	11.4M	9.0M	41K	36.9K	35.1K
Property Plant Equipment	462K	548K	395K	229K	263.4K	337.8K
Non Currrent Assets Other	(1.1M)	356K	46K	96K	6K	5.7K
Net Invested Capital	11.9M	6.7M	22.6M	11.8M	10.4M	7.2M
Net Working Capital	11.0M	5.8M	22.2M	11.5M	10.2M	12.9M
Current Deferred Revenue	267K	1.4M	15K	43K	38.7K	36.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Entera Stock Analysis

When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Entera Price To Sales Ratio vs Capex To Revenue Analysis

Price To Sales Ratio vs Capex To Revenue

Price To Sales Ratio vs Capex To Revenue Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Capex To Revenue

Entera Bio fundamental ratios Correlations

Entera Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Entera Bio fundamental ratios Accounts

Also Currently Popular

Additional Tools for Entera Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Cash

Total Liab	- 0.97	Net Tangible Assets
Total Current Assets	- 0.96	Net Debt
Cash And Short Term Investments	- 0.96	Net Debt
Cash	- 0.96	Net Debt
Non Current Liabilities Total	- 0.96	Net Tangible Assets
Total Liab	- 0.96	Total Stockholder Equity